The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti, Kings College London, London, UK. We asked, Is there a place for immunotherapy in MDS?

Is there a place for immunotherapy in MDS?

Kordasti overviews a network of immune dysregulation in MDS, including inflammation, immunosuppression, and cell death. He highlights heterogeneity in MDS and the need for better stratification of patients undergoing immunotherapy. He finishes by outlining methods to improve patient profiling for future trials, including when to consider immunotherapy.

 

Share: